Spyre Therapeutics, Inc (SYRE)

In the past six months, the CEO sold shares in January 2026. The company announced accelerated clinical trial timelines in January 2026, expecting six proof-of-concept readouts in 2026 from its SKYLINE and SKYWAY clinical trials. Kate Tansey Chevlen was appointed as Chief Commercial Officer in January 2026. Mizuho initiated coverage with an "outperform" recommendation in December 2025. Positive interim Phase 1 results for SPY003 were announced in November 2025. A public offering in October 2025 resulted in a pro forma cash position of $783 million as of September 30, 2025. Phase 2 studies were initiated in August/September 2025. The stock's price increased by 46.04% over the last 12 months, but decreased by 2.44% in the past month. As of December 23, 2025, the share price was $33.24, an increase of 42.42% from December 24, 2024.

Spyre Therapeutics does not currently have revenue-generating products, so there is no discernible demand seasonality. Demand for future products would likely be driven by disease prevalence and treatment guidelines rather than seasonal factors.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated diseases. The company is developing a pipeline of investigational extended half-life antibodies targeting key pathways involved in inflammatory diseases, including SPY001, SPY002, SPY003, SPY072, SPY120, SPY130 and SPY230. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.

Spyre Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.

Spyre Therapeutics generally holds a positive brand reputation due to its promising pipeline and strategic approach. The company has a consensus rating of "Buy" from analysts. Its focus on developing next-generation IBD products is seen as a strength. Positive interim Phase 1 results and accelerated Phase 2 trial timelines contribute positively to its reputation. Strategic asset acquisitions and partnerships have enhanced Spyre's capabilities. The appointment of a Chief Commercial Officer suggests a strategic move towards future commercialization.

Approximately 77% to 82.88% of the company's stock is held by institutional shareholders, insiders own between 6.20% and 33.19% of the stock, and individual investors hold around 11% to 17.83% of the shares. Major institutional owners include FMR LLC, Fairmount Funds Management LLC, BlackRock, Inc., RTW Investments, LP, Tang Capital Management LLC, and Vanguard Group Inc. Fairmount Funds Management LLC is the largest individual shareholder, owning 18.43% of the company.